Intraoperative Neuromonitoring Recording With a Novel SCS Paddle: Phase II

Sponsor
Albany Medical College (Other)
Overall Status
Recruiting
CT.gov ID
NCT05459324
Collaborator
(none)
24
1
11.8
2

Study Details

Study Description

Brief Summary

The purpose of this study is to demonstrate safety and efficacy of a new spinal cord stimulation paddle electrode which is able to target the dorsal horns, dorsal nerve roots, and dorsal columns. The research electrode ("Study Electrode") is designed to answer basic physiological clinical research questions. It may inform future device therapy development, but the Study Electrode is not a product that will be marketed or sold. The Investigators believe the protocol is a Non-Significant Risk study answering basic physiological research questions, which may be performed under hospital IRB approval.

Condition or Disease Intervention/Treatment Phase
  • Device: HD Study Electrode

Study Design

Study Type:
Observational
Anticipated Enrollment :
24 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Effects of Novel SCS Paddle on Intraoperative Neuromonitoring Recording: Phase II
Actual Study Start Date :
Jun 8, 2022
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Study Group

Twenty-four patients offered SCS for standard of care were also invited to participate in this study, in which a study electrode was temporarily placed intraoperatively and neuromonitoring was done per our routine standard-of-care

Device: HD Study Electrode
The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.

Outcome Measures

Primary Outcome Measures

  1. Numeric Rating Scale [3 months]

    Patients rate their pain on a scale from 0-10; 0 being not in pain and 10 being worst pain imaginable. A higher score indicates worse outcome.

Secondary Outcome Measures

  1. McGill Pain Questionnaire (MPQ) [3 month]

    Patients select words that describe their pain. There are a total of 15 words. A higher score (more words selected) indicates worse outcome with a range from 0-15.

  2. Oswestry Disability Index (ODI) [3 months]

    This is a multiple choice style scale where patients are presented with an activity and asked to select a description which best matches their ability to perform that activity. Multiple choice options are then scored on a scale from 0-5; where 0 is no issues performing the activity and 5 is cannot perform activity. A higher score indicates worse outcome. The range in scores is from 0-100.

  3. Pain Catastrophizing Scale (PCS) [3 months]

    Patients are presented with a series of statements and they are asked to rate on a scale from 0-4, how often these statements apply to them when they are in pain. 0= never and 4= always. A higher score indicates worse outcome. Scores range from 0-52.

  4. Beck Depression Index (BDI) [3 months]

    This is a multiple choice style scale where patients are asked to select a statement related to a feeling of sadness or a component of depression. Multiple choice options are then scored on a scale from 0-3; where 0 is they do not feel that way and 3 is they do feel that way. A higher score indicates worse outcome. Scores range from 0-63

Other Outcome Measures

  1. PainDetect [Baseline]

    Ensures patient's pain is neuropathic in nature

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • patients undergoing a spinal cord stimulation procedure for neuropathic pain.

  • Patients must be fluent in English as well as mentally competent to read and answer the questionnaires, as well as complete pain assessment exams.-

  • subjects must be able to give informed consent.

Exclusion Criteria:
  • patients who are not undergoing thoracic spinal cord stimulation for chronic neuropathic pain

Contacts and Locations

Locations

Site City State Country Postal Code
1 Albany Medical College Albany New York United States 12208

Sponsors and Collaborators

  • Albany Medical College

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Albany Medical College
ClinicalTrials.gov Identifier:
NCT05459324
Other Study ID Numbers:
  • 6426 Microleads
First Posted:
Jul 14, 2022
Last Update Posted:
Jul 14, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Albany Medical College
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 14, 2022